Logo Mark
Publications

ASH 2022

All Publications

MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Clinical Imetelstat: MFImetelstat
ASH 2022

Mascarenhas, et al.

An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate-1, Intermediate-2 or High-Risk Myelofibrosis

Clinical Imetelstat: MFImetelstat
ASH 2022

Bradley T, et al.

Imetelstat Achieved Prolonged, Continuous Transfusion Independence in Patients With Heavily Transfused Non-Del(5q) Lower Risk MDS (LR-MDS) Relapsed/Refractory to Erythropoiesis Stimulating Agents Within the IMerge Phase 2 Study

Clinical Imetelstat: MDSImetelstat
ASH 2022

Platzbecker, et al.

Imetelstat-Mediated Alterations in Lipid Metabolism to Induce Ferroptosis As Therapeutic Strategy for Acute Myeloid Leukemia

ImetelstatNon-clinical Imetelstat
ASH 2022

Bruedigam C, et al.

[facetwp facet="publication_load_more"]